Biodexa Pharmaceuticals (BDRX) said Monday that the US Food and Drug Administration granted fast track designation for eRapa to potentially treat familial adenomatous polyposis.
The designation helps facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
The company said it had received US FDA orphan drug designation for eRapa in familial adenomatous polyposis and intends to seek a similar designation in Europe.
Familial adenomatous polyposis universally leads to cancer of the colon and/or rectum if untreated, Biodexa said.
The company's shares were up more than 65% in recent trading.
Price: 6.75, Change: +2.68, Percent Change: +65.85
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。